See more : PT Mitra Keluarga Karyasehat Tbk (MIKA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Amiyaki Tei Co., Ltd. (2753.T) Income Statement Analysis – Financial Results
- Clontarf Energy plc (CLON.L) Income Statement Analysis – Financial Results
- NeoVolta Inc. (NEOVW) Income Statement Analysis – Financial Results
- Manomay Tex India Limited (MANOMAY.BO) Income Statement Analysis – Financial Results
- Real Matters Inc. (RLLMF) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences appoints pharmaceutical industry veteran Dr George Garibaldi to its Scientific Board of Advisors
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has appointed Dr George Garibaldi, who has more than 40 years of experience in drug development and the pharmaceutical industry, to its Scientific Board of Advisors. Dr Garibaldi is the co-founder and...
BioHarvest Sciences CEO projects 3-3.5x revenue growth next year in 2022 shareholder letter
BioHarvest Sciences Inc published a year-end letter to shareholders, highlighting its 2022 production increases and issuing significant revenue projections for 2023. “2022 saw us build foundational capabilities which have already proven to be highly impactful,” CEO Ilan Sobel said in...
BioHarvest Sciences projects 2023 revenue to more than triple as its biotech innovation pays off
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has said it is estimating 2023 revenue to be between $17 million and $20 million, representing growth of at least three times over 2022. The Vancouver-based company said revenue for 2022 is now estimated to be...
BioHarvest Sciences signs 'truly revolutionary' LOI to provide medical-grade cannabis with tailored cannabinoid combinations to drug developers
BioHarvest Sciences Inc has signed a binding letter of intent (LOI) to supply Royal Emerald Pharmaceuticals with unique compositions of cannabis in an effort to develop cures PTSD, pain management, anxiety conditions and more. Royal Emerald is one of seven...
BioHarvest Sciences' placement oversubscribed after attracting significant demand
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has reported significant demand for the second tranche of its placement of convertible notes which has now closed. As a result, the company said it expects the offering to be oversubscribed and therefore intends to close...
BioHarvest Sciences highlights unique cannabis composition with potential medical and commercial implications
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has highlighted the unique composition of one of its Bio CELLicitation-based cannabis products grown from a CBD Hemp plant that the company said has major medical and commercial implications. The company said the analysis of...
BioHarvest Sciences closes first tranche of previously reported oversubscribed private placing for around C$6.9 million
BioHarvest Sciences Inc said it has closed the first tranche of its previously reported oversubscribed private placing of convertible notes, bringing in a principal sum of C$6,878,243.65. As reported on October 7 this year, Vancouver-based BioHarvest Sciences revealed that the...
BioHarvest Sciences increases size of oversubscribed non-brokered private placement of convertible notes
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that its previously announced non-brokered private placement of up to C$6.3 million has been oversubscribed and has now been increased to up to C$10 million to further accelerate VINIA sales growth and its cannabis...
BioHarvest Sciences reports record sales of VINIA in 3Q; cracks the US$1M mark
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said the third-quarter sales orders of its flagship VINIA red grape supplement reached a record of US$1.71 million, representing a 145% growth year-over-year and 81% growth compared to the second quarter of 2022. The company said following the...
BioHarvest Sciences wins sustainability award
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has won The Business Intelligence Group's 2022 Sustainability Leadership Award. The Business Intelligence Group rewards those with vision, creativity and persistence and the awards programs rely on industry leaders who volunteer to read,...
Source: https://incomestatements.info
Category: Stock Reports